We are live on ! Find out more
PCRX icon

Pacira BioSciences

214 hedge funds and large institutions have $3.29B invested in Pacira BioSciences in 2015 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 70 increasing their positions, 66 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 23

120% more funds holding in top 10

Funds holding in top 10: 511 (+6)

87% more capital invested

Capital invested by funds: $1.76B → $3.29B (+$1.53B)

21% more funds holding

Funds holding: 177214 (+37)

6% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 66

39% less call options, than puts

Call options by funds: $29M | Put options by funds: $47.5M

Holders
214
Holders Change
+37
Holders Change %
+20.9%
% of All Funds
5.61%
Holding in Top 10
11
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+120%
% of All Funds
0.29%
New
62
Increased
70
Reduced
66
Closed
23
Calls
$29M
Puts
$47.5M
Net Calls
-$18.5M
Net Calls Change
-$18.2M
Name Holding Trade Value Shares
Change
Change in
Stake
AIG
101
American International Group
New York
$1.78M -$57K -1,007 -4%
SI
102
Stephens Inc
Arkansas
$1.66M +$45.6K +806 +4%
PPA
103
Parametric Portfolio Associates
Washington
$1.66M +$283K +4,995 +30%
HM
104
HealthCor Management
New York
$1.65M +$1.22M +21,500 New
PC
105
Polar Capital
United Kingdom
$1.61M +$345K +6,099 +41%
LCP
106
Legacy Capital Partners
Wisconsin
$1.54M -$34K -600 -3%
Citigroup
107
Citigroup
New York
$1.54M -$536K -9,465 -32%
BG
108
BlackRock Group
United Kingdom
$1.5M +$33.2K +586 +3%
OPPM
109
Opus Point Partners Management
New York
$1.47M -$107K -1,890 -9%
DekaBank Deutsche Girozentrale
110
DekaBank Deutsche Girozentrale
Germany
$1.44M +$17K +300 +2%
WSA
111
Wall Street Associates
California
$1.36M +$330K +5,828 +49%
Group One Trading
112
Group One Trading
Illinois
$1.24M +$148K +2,622 +19%
Jane Street
113
Jane Street
New York
$1.18M +$871K +15,379 New
Neuberger Berman Group
114
Neuberger Berman Group
New York
$1.09M -$14.7M -259,201 -95%
EGM
115
Engineers Gate Manager
New York
$1M +$741K +13,094 New
DCM
116
Dupont Capital Management
Delaware
$997K +$735K +12,989 New
BAMCO Inc
117
BAMCO Inc
New York
$992K +$341K +6,023 +87%
Asset Management One
118
Asset Management One
Japan
$939K -$4.01M -70,804 -86%
TAM
119
Tocqueville Asset Management
New York
$914K +$674K +11,900 New
AP
120
AHL Partners
United Kingdom
$889K +$655K +11,567 New
Two Sigma Investments
121
Two Sigma Investments
New York
$857K -$332K -5,855 -34%
CSS
122
Cubist Systematic Strategies
Connecticut
$837K -$606K -10,699 -50%
SEI Investments
123
SEI Investments
Pennsylvania
$808K -$253K -4,475 -30%
FMT
124
First Mercantile Trust
Tennessee
$791K +$583K +10,303 New
USAA
125
United Services Automobile Association
Texas
$722K -$442K -7,800 -45%

PCRX Hedge Fund Activity: Q4 2015 in Review

214 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2015, worth a combined $3.29B — up 87% from $1.76B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new PCRX positions and 23 closed out — a net gain of 39 holders — while 70 added to existing stakes and 66 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was Ameriprise, cutting an estimated $52.9M.

  • 214 institutional investors held Pacira BioSciences (PCRX) as of Q4 2015, up from 177 in Q3 2015.
  • Funds reported $3.29B of Pacira BioSciences stock for Q4 2015, up 87% quarter-over-quarter.
  • 62 funds opened new Pacira BioSciences positions in Q4 2015 and 23 closed out, a net change of +39 holders.
  • The largest Pacira BioSciences buyer in Q4 2015 was Fidelity Investments, an estimated $53.1M added.
  • The largest Pacira BioSciences seller in Q4 2015 was Ameriprise, an estimated $52.9M sold.

Based on aggregated 13F filings for Q4 2015.